Industrial production of β-lactam antibiotics

被引:421
作者
Elander, RP [1 ]
机构
[1] Bristol Myers Squibb Co, New York, NY 10154 USA
关键词
D O I
10.1007/s00253-003-1274-y
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The industrial production of beta-lactam antibiotics by fermentation over the past 50 years is one of the outstanding examples of biotechnology. Today, the beta-lactam antibiotics, particularly penicillins and cephalosporins, represent the world's major biotechnology products with worldwide dosage form sales of similar toUS$ 15 billion or similar to65% of the total world market for antibiotics. Over the past five decades, major improvements in the productivity of the producer organisms, Penicillium chrysogenum and Acremonium chrysogenum (syn. Cephalosporium acremonium) and improved fermentation technology have culminated in enhanced productivity and substantial cost reduction. Major fermentation producers are now estimated to record harvest titers of 40-50 g/l for penicillin and 20-25 g/l for cephalosporin C. Recovery yields for penicillin G or penicillin V are now >90%. Chemical and enzymatic hydrolysis process technology for 6-aminopenicillanic acid or 7-aminocephalosporanic acid is also highly efficient (similar to80-90%) with new enzyme technology leading to major cost reductions over the past decade. Europe remains the dominant manufacturing area for both penicillins and cephalosporins. However, due to ever increasing labor, energy and raw material costs, more bulk manufacturing is moving to the Far East, with China, Korea and India becoming major production countries with dosage form filling becoming more dominant in Puerto Rico and in Ireland.
引用
收藏
页码:385 / 392
页数:8
相关论文
共 34 条
  • [1] STRUCTURE AND ABSOLUTE-CONFIGURATION OF THIENAMYCIN
    ALBERSSCHONBERG, G
    ARISON, BH
    HENSENS, OD
    HIRSHFIELD, J
    HOOGSTEEN, K
    KACZKA, EA
    RHODES, RE
    KAHAN, JS
    KAHAN, FM
    RATCLIFFE, RW
    WALTON, E
    RUSWINKLE, LJ
    MORIN, RB
    CHRISTENSEN, BG
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1978, 100 (20) : 6491 - 6499
  • [2] BARBER M, 2000, CEPHALOSPORINS BUSIN
  • [3] Barber M, 1996, PENICILLINS BUSINESS
  • [4] Genetic engineering approach to reduce undesirable by-products in cephalosporin C fermentation
    Basch, J
    Chiang, SJ
    [J]. JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY, 1998, 20 (06) : 344 - 353
  • [5] Molecular regulation of β-lactam biosynthesis in filamentous fungi
    Brakhage, AA
    [J]. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 1998, 62 (03) : 547 - +
  • [6] NATURALLY-OCCURRING BETA-LACTAMASE INHIBITORS WITH ANTIBACTERIAL ACTIVITY
    BROWN, AG
    BUTTERWORTH, D
    COLE, M
    HANSCOMB, G
    HOOD, JD
    READING, C
    [J]. JOURNAL OF ANTIBIOTICS, 1976, 29 (06) : 668 - 669
  • [7] CLONING AND EXPRESSION OF A HYBRID STREPTOMYCES-CLAVULIGERUS CEFE GENE IN PENICILLIUM-CHRYSOGENUM
    CANTWELL, CA
    BECKMANN, RJ
    DOTZLAF, JE
    FISHER, DL
    SKATRUD, PL
    YEH, WK
    QUEENER, SW
    [J]. CURRENT GENETICS, 1990, 17 (03) : 213 - 221
  • [8] CANTWELL CA, 1992, P R SOC LONDON B, V238, P283
  • [9] CHIANG SJ, 1991, 50 YEARS PENICILLIN, P245
  • [10] CHIANG SJD, 1999, ENCY BIOPROCESS TECH, V1, P560